Early news from Solbec’s SBP002: no toxicity
20 July, 2004 by Graeme O'NeillPerth biotech Solbec Pharmaceuticals (ASX:SPB) is confident of taking its promising cancer drug SBP002 into Phase II clinical trials after a midstream review of data from its current phase 1 trial.
Xenome starts Phase I trial of pain drug
20 July, 2004 by Graeme O'NeillUnlisted Brisbane biotech Xenome has initiated a Phase I clinical trial of its lead candidate for treating neuropathic pain, Xen2174.
Epitan goes shopping: acquires three dermatology products
19 July, 2004 by Melissa TrudingerEpitan (ASX: EPT) has acquired three dermatological products in its push to become a specialty dermatology pharmaceuticals company.
Burrill fund frustrated by lack of local support
19 July, 2004 by Renate KrelleThe Burrill Australia Life Science Fund has raised AUD$150 of its planned $200 million venture capital fund in just over a year -- but more than half of it comes from overseas institutions.
Pest CRC moves to Qld as southern GM bans bite
16 July, 2004 by Graeme O'NeillQueensland's biotechnology industry is beginning to capitalise on southern discomfort over genetically modified (GM) organisms, with the Cooperative Research Centre for Pest Animal Control (CRC-PAC) shifting its research team from Gungahlin, in Canberra, to the Institute of Molecular Biology at the University of Queensland.
Seventh patient implanted with Ventracor artificial heart
15 July, 2004 by Renate KrelleThe seventh patient has been implanted with Ventracor's (ASX:VCR) VentrAssist left ventricular assistance device as part of the company's pilot trial at the Alfred Hospital in Melbourne.
Biting back: QRxPharma to test 20 deadliest snake venoms
14 July, 2004 by Graeme O'NeillIn 1967, Gosford reptile expert Athol Compton suffered a shallow, grazing bite to his thumb while attempting to capture an unfamiliar, large light brown snake with a dark head in Corner Country, in far southwest Queensland.
BioDiem’s antimicrobial joins the field
14 July, 2004 by Graeme O'NeillMelbourne biotechnology company BioDiem Limited (ASX:BDM) has reported promising results from the first field trial of its BDM-I antimicrobial as a poultry feed additive.
Progen begins phase II PI-88 trial in Taiwan
14 July, 2004 by Graeme O'NeillBrisbane oncology drug developer Progen Industries (ASX:PGL, NASDAQ:PGLAF) today announced it has begun the fourth and largest Phase II clinical trial of its lead anti-cancer drug PI-88 in patients who have undergone surgery for primary liver cancer.
ChemGenex raises $6.2 million
14 July, 2004 by Melissa TrudingerChemGenex Pharmaceuticals (formerly AGT Biosciences; ASX: CXS) has raised AUD$6.2 million through a 15 per cent placement to existing and new shareholders at $0.48 per share, a discount of almost 15 per cent to yesterday's closing price of $0.56.
Phenomix signs collaboration deal with Genentech
13 July, 2004 by Melissa TrudingerCanberra and San Diego-based Phenomix has signed a multi-year collaboration agreement with Genentech to identify and prioritise drug target for immune disorders.
In brief: Eqitx, Stirling Products
12 July, 2004 by Iain ScottTwo Perth-based biotechs have made key executive appointments.
Industry encouraged to make use of synchrotron
12 July, 2004 by Melissa TrudingerThe head of a new advisory committee for the Australian synchrotron has urged industry to make sure it could get maximum use of the new Australian synchrotron.
Researchers push big pharma to rethink asthma treatment
12 July, 2004 by Melissa TrudingerResearchers at the Telethon Institute for Child Health Research in Perth are hoping to persuade big pharma to test therapeutics targeting specific inflammatory response effector molecules in young children at risk of developing persistent asthma.
GSK to wind up Biota hep C partnership
09 July, 2004 by Iain ScottDrug firm GlaxoSmithKline has told the US subsidiary of Melbourne-based Biota Holdings (ASX:BTA) that it will not extend the companies' research collaboration on novel hepatitis C drugs beyond its scheduled expiry date of August 9.
